IntelGenx Corp. has focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems to separate themselves from the competition in the medical sector. Today, IntelGenx took a major step forward with the announcement that they have entered a definitive agreement with RedHill Biopharma for an Anti-Migraine film product. The product is intended for the rapid relief of migraines and will be the first oral thin film product based upon IntelGenx’s proprietary VersaFilm technology.

The terms of this co-development and commercialization agreement will have Red Hill obtaining certain exclusive rights to market and sell the oral film product. In exchange for these rights, IntelGenx will receive external development fees totaling up to $2.1 million from RedHill and, depending on the circumstance, up to 75% of all proceeds for the worldwide sale of the product.

Leading the way at IntelGenx is Dr. Horst G. Zerbe who serves as the company’s President and CEO. When asked about this agreement, Dr. Zerbe was quoted as saying, “We are pleased to be working with RedHill on our anti-migraine film product. This partnership helps validate and accelerate IntelGenx’ VersaFilm technology, while providing IntelGenx with additional resources to meet our ongoing strategic objectives in developing additional oral film products.”

To learn more about the IntelGenx Corporation, visit the company website at: www.intelgenx.com.